The amniotic membrane is the innermost layer of fetal membrane that is taken from a woman's placenta and utilized as a transplant material for cases such as severely burned skin, trauma wounds, chronic wounds, and other conditions. Initially, an amniotic membrane was employed as a skin graft substrate (skin transplantation surgery). Amniotic membranes can also be employed in ophthalmic surgery, aesthetic surgery, anticancer treatment, and regenerative medicine, according to the National Centre of Biotechnology Information (NCBI). Because of its non-immunogenicity, anti-scarring properties, antibacterial properties, and capacity to control inflammation, an amniotic membrane is chosen.
The Impact of the Coronavirus (COVID-19) Pandemic on the Global Amniotic Membrane Market
On December 31, 2019, a Coronavirus (COVID-19) epidemic was first detected in Wuhan, China. COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. According to the World Health Organization's Coronavirus (COVID-19) Weekly Epidemiological Update, coronavirus disease (COVID-19) caused approximately 169 million cases and 3.5 million deaths worldwide till May 30, 2021.
COVID-19's Effect on Amniotic Membrane Demand and Supply
The COVID-19 pandemic and lockdown in several countries throughout the world has had an impact on enterprises in all sectors, including the private healthcare sector. The COVID-19 pandemic has had a significant influence on the healthcare Amniotic Membrane Market whole supply chain, owing to stringent lockdown in certain places. The COVID-19 epidemic has had three main effects on the economy of various places throughout the world: 1) direct effects on production and demand; 2) disruptions in distribution routes; and 3) financial impact on firms and financial markets. Many countries, including Thailand, Indonesia, and Singapore, are experiencing difficulties with healthcare product transportation and distribution.
Competitive Landscape of the Global Amniotic Membrane Market
Smith & Nephew, Applied Biologics, Organogenesis Holdings Inc., Osiris Therapeutics, Inc., Alliqua BioMedical, Inc., Amnio Technology, LLC, Next Biosciences, Integra LifeSciences, MiMedx, LifeCell International, Human Regenerative Technologies, LLC, Amniox Medical, Inc., Wright Medical, TissueTech, Katena Products, Inc., NuVision Biotherapies, Surgenex
0 Comments